Cigna Group

Cigna built and deployed PXDX — a procedure-to-diagnosis matching system that allowed its employed physicians to batch-deny insurance claims in under two seconds each, without opening a single patient file. In 2022, ProPublica reviewed Cigna records showing more than 300,000 denials in two months. Dr. Cheryl Dopke denied approximately 60,000 claims in a single month. Dr. Richard Capek denied more than 80,000 in two months. Dr. Paul Rossi denied more than 63,000. The average time spent per denial: 1.2 seconds. The company's own data showed 80% of PXDX denials were overturned when patients appealed. Cigna's own projection was that only 5% of patients would appeal. The math was the design. CEO David Cordani earned $23.25 million in 2024 while presiding over this system.

• —ProPublica (March 2023) reviewed Cigna records showing 300,000+ denials in a two-month period, with individual physicians averaging 1.2 seconds per claim in batch processing.
• —Dr. Alan Muney, who developed the system over a decade, stated directly: "The PXDX stuff is not reviewed by a doc or nurse or anything like that." On its financial impact: "It has undoubtedly saved billions of dollars."
• —Ron Howrigon, former Cigna executive: "They were paying all these claims before. Then they weren't. You're talking about a system built to deny claims."
• —A former Cigna doctor described the process: "We literally click and submit. It takes all of 10 seconds to do 50 at a time."
• —The 80% appeal reversal rate means PXDX denials are wrong four out of five times — when patients navigate the process. Cigna projected that 95% of patients would absorb the denial without fighting back. That projection was the product's value proposition.
• —The House Committee on Energy and Commerce requested Cigna corporate documents on the PXDX system. Multiple state and federal regulators initiated examinations of the system\'s legality.
• —A federal class action was filed in the Eastern District of California alleging Cigna violated California law requiring "thorough, fair and objective" investigation into each claim. A judge advanced the class claims in 2023.

Nataline Sarkisyan was 17 years old and had leukemia. After a bone marrow transplant caused liver failure, her physicians at UCLA recommended a liver transplant. On December 11, 2007, Cigna denied coverage, classifying the procedure as "experimental, investigational and/or unproven." The head of the UCLA transplant unit wrote a protest letter stating the procedure was neither experimental nor unproven. Cigna reversed the decision after a CNN-covered public protest outside its Glendale, California offices. Nataline died within hours of the reversal — before the transplant could be performed. Her family filed a wrongful-death suit. It was dismissed. A 1987 Supreme Court ruling under ERISA shields employer-paid health plans from damages when coverage is denied — even when the denial causes death. No one at Cigna was charged.

• —Nataline Sarkisyan, 14, was diagnosed with leukemia. By Thanksgiving 2007 she had received a bone marrow transplant from her brother. Liver failure followed as a complication. Her physicians recommended a liver transplant.
• —December 11, 2007: Cigna denied the liver transplant claim, calling the procedure "experimental, investigational and/or unproven." The UCLA transplant unit chief wrote a formal protest stating this characterization was wrong.
• —CNN and other outlets covered a public protest outside Cigna's Glendale, California offices. Cigna reversed the decision and agreed to pay.
• —Nataline died within hours of the reversal. The transplant never occurred.
• —The family's wrongful-death suit was dismissed under the ERISA preemption doctrine — Pilot Life Ins. Co. v. Dedeaux, 1987 Supreme Court ruling. Under ERISA, employer-sponsored health plan members cannot recover damages for coverage denials that cause death or injury; the only available remedy is the cost of the benefit denied. The law was designed this way, with sustained insurance-industry lobbying over decades.
• —Cigna faced no criminal exposure. The case produced no lasting regulatory change. The legal architecture of impunity remained intact.

The Department of Justice filed a civil fraud lawsuit against Cigna in 2020 alleging $1.4 billion in false Medicare Advantage claims between 2012 and 2017. The mechanism: Cigna's "360 Program" paid primary care physicians $150 per completed health assessment and $1,000 for attending training seminars, structured to generate additional diagnoses — including conditions patients did not have, had not been treated for, and that were not in their medical records. These inflated diagnoses raised "risk scores" under Medicare Advantage, driving higher federal payments per patient. The diagnoses were not clinically documented and were not reliable. Cigna paid $172 million to settle the case in 2024. No executives were charged.

• —DOJ USAO-SDNY filed the civil fraud suit in 2020. The complaint alleged Cigna submitted false diagnostic codes for health conditions patients did not have — for five consecutive years — to inflate Medicare Advantage risk-adjustment payments.
• —The "360 Program": primary care physicians received $150 for each completed 360 health assessment. Doctors attending seminars on the program received $1,000. The program was structured to generate additional diagnoses, not to improve patient care.
• —Medicare Advantage pays insurers per member at rates set by "risk score" — the sicker the profile, the higher the federal payment. Adding diagnoses patients don't have or haven't been treated for inflates payments without delivering additional care.
• —Cigna paid $172 million to settle the False Claims Act allegations in 2024. No executives were charged. The settlement represents approximately 12% of the alleged $1.4 billion in fraudulent payments.
• —The DOJ's willingness to settle for 12 cents on the fraudulent dollar is itself part of the pattern this site documents: regulatory enforcement calibrated to not threaten business models.

The Employee Retirement Income Security Act of 1974 (ERISA), as interpreted by the Supreme Court in 1987, effectively prevents patients from recovering damages when their employer-sponsored health plan wrongfully denies coverage — even when the denial causes death. The only available remedy is the cost of the benefit denied. When Nataline Sarkisyan died after Cigna reversed its denial, her family could not sue for wrongful death. When PXDX generated 300,000 denials in two months with an 80% reversal rate, the patients who absorbed those denials silently had no actionable claim under federal law. Cigna and the insurance industry spent decades lobbying for and preserving this legal architecture. Multi-state AG investigations in 2013 resulted in California fines of $2M+ for Cigna's disability claim violations — a trivial cost relative to the revenue from the denied conduct.

• —Pilot Life Ins. Co. v. Dedeaux, 481 U.S. 41 (1987): The Supreme Court ruled that ERISA preempts state-law claims for bad-faith insurance practices in employer-sponsored plans. A patient whose coverage is wrongfully denied cannot sue under state tort law; the only remedy is the value of the benefit itself.
• —The practical result: denying a $350 vitamin D test, a $10,000 post-surgical course of treatment, or a liver transplant has no legal exposure beyond being required to pay for the benefit — eventually, and only if the patient appeals. If the patient dies, the estate collects nothing.
• —The insurance industry's lobbying apparatus maintained this preemption for decades against sustained legislative efforts to create a "patients' bill of rights." The ERISA shield is not an accident of law; it is an industry achievement.
• —The 2013 multi-state AG action (Connecticut, California, Massachusetts, Maine, Pennsylvania) found Cigna ignored Social Security disability determinations, ignored independent physician opinions, and failed to include Workers\' Compensation records in coverage decisions. California fines: $2M+. Revenue from denied conduct: immeasurable.
• —California appeared on the American Consumer Satisfaction Index's "most hated companies" list in 2015 and 2018. Consumer sentiment is a leading indicator; enforcement is a lagging one.